FDA Expands Aethlon Hemopurifier IDE To Address Ebola
This article was originally published in The Gray Sheet
Executive Summary
The agency approved an expanded clinical trial allowing Aethlon to test an Ebola treatment protocol at 10 U.S. sites; requires the company to gain institutional review board approval from each institution and the trials can only enroll up to 20 patients.
You may also be interested in...
FDA Emergency Authorizes Roche Ebola Assay
FDA grants its seventh Ebola diagnostic EUA, this time to Roche, as global health officials continue efforts to try to contain the outbreak of the deadly disease in West Africa.
WHO Launches Initiatives For Ebola POC Tests
The World Health Organization has initiated a rapid review process and is providing early test validation materials to encourage more manufacturers to quickly develop rapid, point-of-care Ebola tests. Meanwhile, Aethlon Medical is providing its bio-filtration device to treat blood of Ebola patients.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.